Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant Human Papillomaviruses Chimeric Virus-like Particles (HPV VLPs) are produced in Baculovirus/Insect cell expression system, assembled with L1 major capsid protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. HPV VLPs can be used in the development of HPV diagnostics and in vaccine development and R&D (including use as an immunogen).
Product Specifications
Structural Proteins
L1 protein
Expression Systems
Baculovirus/Insect cell expression system (please specify if other expression system is needed)
Form
Liquid
Alternative Names
Human Papillomaviruses Chimeric Virus-like Particles; HPV VLPs; HPV; Human Papillomaviruses; VLP; Virus-like particle
Storage
Store at -80 °C long term. Avoid repeated freeze/thaw cycles.
Virus Background
Virus Family
Papillomaviridae
Virus Species
Human Papillomaviruses
Virus Overview
Human papillomavirus (HPV) is a small, non-enveloped deoxyribonucleic acid (DNA) virus that infects skin or mucosal cells. The circular, double-stranded viral genome is approximately 8-kb in length. The genome encodes for 6 early proteins responsible for virus replication and 2 late proteins, L1 and L2, which are the viral structural proteins. At least 13 of more than 100 known HPV genotypes can cause cancer of the cervix and are associated with other anogenital cancers and cancers of the head and neck. The two most common "high-risk" genotypes (HPV 16 and 18) cause approximately 70% of all cervical cancers. HPV was estimated to cause almost half a million cases and 250,000 deaths from cervical cancer in 2002, of which about 80% occurred in developing countries. Results showed that expression of L1 alone led to the production of virus-like particles (VLPs) which morphologically resemble the authentic HPV virions but contain no viral DNA. These VLPs are produced by self-assembly of the L1 protein when expressed in a heterologous cell substrate. HPV VLPs are highly immunogenic in mice or rabbits, and the resulting antibodies have been shown to be neutralizing and type restricted when tested in a pseudovirion neutralization assay.